Correlation of Significantly Decreased Serum Circulating Mesencephalic Astrocyte-Derived Neurotrophic Factor Level With an Increased Risk of Future Cardiovascular Disease in Adult Patients With Growth Hormone Deficiency.

Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE

Original Publication: [Lausanne : Frontiers Research Foundation]

Biomarkers/*blood ; Cardiovascular Diseases/*diagnosis ; Growth Disorders/*complications ; Nerve Growth Factors/*blood; Adult ; Aged ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/etiology ; Case-Control Studies ; Female ; Follow-Up Studies ; Humans ; Insulin Resistance ; Male ; Middle Aged ; Prognosis ; Risk Factors ; Young Adult

Objective: Adult growth hormone deficiency (AGHD) is a rare chronic inflammatory disease caused by damage to the pituitary gland and is accompanied by disorders of multiple metabolic pathways. By examining the correlation between the serum mesencephalic astrocyte-derived neurotrophic factor (MANF) levels of AGHD patients and those of normal controls, we hope to elucidate the close relationship among MANF, lipid metabolism and insulin resistance in AGHD and discuss the potential therapeutic value of MANF.
Methods: This study included 101 AGHD patients and 100 healthy subjects matched for sex, age, height, and weight. Anthropometric parameters and biochemical indicators such as body mass index, waist circumference, hip circumference, serum MANF level, blood lipids and insulin level were measured. The above patients were also divided into several subgroups for correlation analysis based on indicators such as insulin resistance and BMI.
Results: The serum circulating MANF content of AGHD patients was significantly lower than that of the normal control group (5.235 (0.507-17.62) ng/ml (n=101) vs. 10.30 (1.84-16.65) ng/ml (n=100); p<0.0001), and circulating MANF levels were linearly correlated with HOMA-IR in the AGHD population (R=0.481, P=0.0041). When MANF was at pathological concentrations (lower than the mean circulating MANF of normal controls), the lowest concentration tertile (OR=21.429 p<0.0001) had a significantly higher disease odds ratio, Framingham risk score and 10-year risk of atherosclerotic cardiovascular disease than the highest concentration tertile.
Conclusions: MANF has a significant correlation with insulin resistance in the AGHD state. There is a strong correlation with abnormal glucose and lipid metabolism in the obese AGHD population. MANF is also a good assessment factor for the risk of cardiovascular disease in AGHD patients and has excellent therapeutic potential.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Ren, Wang, Chen, Long, Zhang, Wu, Qian, Chen, Liu and Ren.)

Front Endocrinol (Lausanne). 2019 Nov 06;10:765. (PMID: 31781038)
Endocr J. 2017 Apr 29;64(4):403-410. (PMID: 28216543)
BMC Cardiovasc Disord. 2005 Sep 08;5:26. (PMID: 16150143)
Trends Mol Med. 2012 Jan;18(1):59-68. (PMID: 21889406)
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9867-72. (PMID: 12897244)
J Mol Cell Cardiol. 2011 Oct;51(4):512-7. (PMID: 20970425)
J Mol Neurosci. 2003 Apr;20(2):173-88. (PMID: 12794311)
J Biol Chem. 2011 Sep 2;286(35):30344-30351. (PMID: 21757703)
Endocr J. 2015;62(12):1037-48. (PMID: 26300280)
Trends Cardiovasc Med. 2006 Aug;16(6):183-8. (PMID: 16839860)
Mutat Res. 2005 Jan 6;569(1-2):29-63. (PMID: 15603751)
Endocr Pract. 2018 Jan;24(1):33-39. (PMID: 29144802)
Nature. 2007 Jul 5;448(7149):73-7. (PMID: 17611540)
Diabetes Obes Metab. 2019 Apr;21(4):975-983. (PMID: 30536884)
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7324-9. (PMID: 10377413)
Nutr Metab Cardiovasc Dis. 2017 Oct;27(10):881-889. (PMID: 28851556)
J Biol Chem. 2012 Jul 27;287(31):25893-904. (PMID: 22637475)
Lipids Health Dis. 2011 Oct 19;10:183. (PMID: 22011564)
Diabetes Care. 2010 Apr;33(4):920-2. (PMID: 20067971)
J Clin Endocrinol Metab. 2011 Jun;96(6):1587-609. (PMID: 21602453)
Endocr Pract. 2019 May;25(5):446-453. (PMID: 30657359)
Neurobiol Dis. 2017 Jan;97(Pt B):90-102. (PMID: 27425895)
Mol Cell Neurosci. 2008 Nov;39(3):356-71. (PMID: 18718866)
Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102. (PMID: 22251901)
Circulation. 2016 Nov 8;134(19):1430-1440. (PMID: 27682885)
Biofactors. 2020 Jul;46(4):629-636. (PMID: 32196782)
Horm Metab Res. 2020 Feb;52(2):109-116. (PMID: 32067218)
Circulation. 2008 Jul 8;118(2):124-30. (PMID: 18591432)
Transl Res. 2017 Oct;188:1-9. (PMID: 28719799)
J Clin Endocrinol Metab. 1987 Mar;64(3):596-601. (PMID: 3493255)
Endocr Rev. 2009 Apr;30(2):152-77. (PMID: 19240267)
Nat Commun. 2017 Sep 18;8(1):579. (PMID: 28924165)
Front Physiol. 2018 Nov 29;9:1725. (PMID: 30555354)
Ceylon Med J. 2011 Jun;56(2):59-61. (PMID: 21789866)
Cell Rep. 2014 Apr 24;7(2):366-375. (PMID: 24726366)
Vasc Endovascular Surg. 2016 Feb;50(2):107-18. (PMID: 26983667)
Am J Chin Med. 2019;47(1):97-117. (PMID: 30776912)
Pharmacol Rev. 1994 Mar;46(1):1-34. (PMID: 8190748)

Keywords: adult growth hormone deficiency; cardiovascular risk; insulin resistance; lipid metabolism; mesencephalic astrocyte-derived neurotrophic factor

0 (Biomarkers)
0 (MANF protein, human)
0 (Nerve Growth Factors)

Date Created: 20210705 Date Completed: 20211220 Latest Revision: 20211220

20231215

PMC8242342

10.3389/fendo.2021.671126

34220710